A three-day congress at Messe Basel where research and development data teams from the major pharmaceutical companies work through drug-discovery AI, bioinformatics, real-world evidence and clinical machine learning, run by Terrapinn as the data and AI counterpart to its separate biologics and US events.
BioTechX Europe is an annual three-day business congress on applied data science, artificial intelligence and genomics across pharmaceutical research and development, held at Messe Basel in Switzerland. Its own tagline is "Data. AI. Discovery. Healthcare." The programme runs across three named hubs, Discovery Disrupted, Data Unleashed and Healthcare 4.0, covering drug-discovery AI, bioinformatics, data architecture, real-world evidence, clinical AI and multi-omics. It is organised by Terrapinn, which also runs a separate BioTechX USA edition and, at the same Basel venue the following week, an unrelated biologics event.
6 to 8 October 2026. Messe Basel, Basel, Switzerland. The organiser's own site gives no street address or hall number for this specific congress; Messe Basel's own site places the exhibition and congress centre at Messeplatz in central Basel. No date or venue change has been found against this edition: 2026 is the currently listed slot, sourced directly from the live event pages on 2026-09-11.
Terrapinn Holdings Ltd, a UK-headquartered business-to-business events company. General enquiries on record: Zahid Tharia, enquiry.uk@terrapinn.com. The account contact named across the event's own pages is Davide Stefan Russano. Speaker applications are handled by Anna Abiola, anna.abiola@terrapinn.com. Sponsorship enquiries go to Jack Bebb, jack.bebb@terrapinn.com, and Jordan Lavender, jordan.lavender@terrapinn.com. Terrapinn separately runs BioTechX USA in Boston and, at Messe Basel the week after this congress, the Festival of Biologics Basel, an unrelated event on antibody therapies, cell and gene therapies and biosimilars: none of these three share a badge with BioTechX Europe.
The organiser states 3,000+ attendees, 400+ speakers, 150+ exhibitors and 100+ biotech start-ups, none of these figures independently audited. The event is business-to-business: the organiser's own material states it is not open to the general public. Read from the published speaker and sponsor rosters, the room is dominated by pharmaceutical R&D data and AI functions (chief data officers, heads of digital biology, AI product owners) from companies including Novartis, Roche, Novo Nordisk, AstraZeneca, Bayer, UCB, Boehringer Ingelheim and Sanofi, alongside bioinformaticians, data scientists and the specialist software vendors that sell into that function.
The official page is headed "Confirmed 2026 Speakers" and lists several hundred names spanning pharmaceutical companies, universities, hospitals and vendors, from Rana Abou Antoun (Commercial Director Cell & Gene International, Novartis) and Nabil Adam (Professor Emeritus, Rutgers University) through the alphabet. Five names sit in the database record and are confirmed present on that same page with matching titles:
Treat this as the published roster rather than a final running order: the page carries no session-by-session assignment and is subject to change before October.
The database's own prior edition record shows no attendee, speaker or exhibitor count logged for 2026, so no year-on-year comparison can be drawn from it. Against the organiser's own published stats, this year's headline scale, 3,000+ attendees, 400+ speakers, 150+ exhibitors, 100+ start-ups, matches what the site has stated consistently across the pages checked for this fiche; no separate figure for a prior edition was found to compare it against. What can be read as new for 2026 is the programme structure itself: three named hubs (Discovery Disrupted, Data Unleashed, Healthcare 4.0) running across ten concurrent theatre tracks, plus a pre-scheduled 1:1 meeting system, BioTechX Connect, offered as part of the complimentary pharma and biotech pass.
Ten concurrent theatre tracks are named across the three hubs: AI in Drug Discovery and Development, Cheminformatics, Large Language Models and Bioinformatics + In Silico R&D under Discovery Disrupted; Data Management Storage and Architecture and Data Integration + FAIR under Data Unleashed; Digital Health, Clinical Trials, Real World Data and Evidence and AI in Clinical Trials under Healthcare 4.0. Published session titles include a keynote on "How AI is changing drug discovery at Novartis" and a roundtable on "AI in Model-Informed Drug Development" and a panel on "Build, Buy, or Partner: From Agentic AI Hype to Enterprise Value". The day-by-day structure runs opening keynotes and parallel theatre sessions on 6 October, senior decision-maker sessions and further keynotes on 7 October, and closing theatre programming on 8 October. At the level of subject rather than track name, the programme record for this event names nine themes: AI in drug discovery, large language models in pharma, bioinformatics, real-world evidence, AI in clinical trials, genomics and multi-omics, AI for imaging, digital twins and federated learning; the first five map directly onto the theatre tracks above, the remaining four (genomics and multi-omics, AI for imaging, digital twins, federated learning) sit inside the Discovery Disrupted and Data Unleashed hubs without a matching standalone track name on the current agenda page.
Six formats are named on the organiser's own agenda and conference pages: keynote addresses, ten parallel theatre tracks, roundtable discussions, panel discussions, startup pitches and poster sessions. In addition, BioTechX Connect offers pre-scheduled one-to-one meetings, described by the organiser as four 15-minute slots, available to delegates who take a General Admission with Networking pass or the complimentary pharma and biotech pass. The database record for this event's matchmaking field says none is offered; the organiser's own pages describe BioTechX Connect in detail, so the fiche follows the site.
None found sharing this congress's badge or dates. BioTechX Europe runs alone at Messe Basel on 6 to 8 October 2026: no co-located Terrapinn show at the same venue on the same dates was found in the pages checked for this fiche. The venue hosts a second, unrelated Terrapinn event the following week, the Festival of Biologics Basel, 13 to 15 October 2026, covering antibody therapies, cell and gene therapies, immunotherapies and biosimilars; it is a separate congress with its own registration and its own badge, not a co-located or shared-ticket event with BioTechX Europe. No World Vaccine Congress Europe or standalone Cell and Gene Therapy congress was found sharing Messe Basel with BioTechX Europe this October. A reader who has seen BioTechX bundled with other Terrapinn shows at other venues or in other years should not assume that pattern holds here.
Two paid tiers are published on the organiser's own registration page. General Admission without Networking: €2,995 standard, €2,795 with the early-bird discount, or €2,235 per person for groups of three or more, all before 18 September 2026. General Admission with Networking, which adds exhibitor and attendee contact through the event app and 1:1 meeting arrangement: €3,995 standard, €3,795 early-bird, or €3,035 per person for groups of three or more, same 18 September deadline. The organiser also states larger group discounts of 40% for five or more and 50% for ten or more passes, applied at checkout. Two complimentary routes exist: a free pass for pharma, biotech, academia and healthcare staff, conditional on committing to six BioTechX Connect meetings, and a free press and media pass. The event's own landing page separately advertises "TICKETS FROM €2,695" (unverifiable information): that figure does not match any tier shown on the actual registration page, whose lowest published price is €2,795, and it may be a stale banner from an earlier pricing phase. The database record for this event holds a lower figure still, "from 2,495 EUR", which is now below every tier on the live registration page.
Through an "Apply to speak" link on the conference page, routing to the organiser's booking system, with Anna Abiola, anna.abiola@terrapinn.com, named as the speaker contact. No published call for papers, submission deadline or selection criteria was found; the process reads as an expression-of-interest form reviewed by the organiser rather than an open call.
Through the organiser's booking system, or by contacting the named sponsorship leads, Jack Bebb (jack.bebb@terrapinn.com) and Jordan Lavender (jordan.lavender@terrapinn.com). A downloadable prospectus is offered from the same page. No public rate card was found; the tier structure actually sold is visible instead, from the sponsors and exhibitors page.
Published sponsor list, by tier, as it stood in September 2026:
Sixty or more further exhibitors are listed without a sponsorship tier, including TheraPanacea, BioBox, ChapsVision, Chryselys, Collaborative Drug Discovery and Domino Data Lab, and a separate startup zone lists names including ALLOX, Alp Bio, Combinatics, Daltontx, EQTY Lab, Kubidat and Mycolever. A further set of national and professional associations appears on the site as partners rather than sponsors, among them the BioIndustry Association, Swiss Biotech Association, Asebio, hollandbio and scienceindustries; none of these carries a media-partner label, and the database record for this event holds no media partner. Novo Nordisk appears both as a Gold sponsor and, separately, in the speaker roster, through its Head of Digital Biology, AI & Digital Innovation.
Two distinct populations, read from the rosters rather than from any stated breakdown. Among speakers, large multinational pharmaceutical companies dominate, through their R&D data and AI functions specifically: Novartis, Roche, Novo Nordisk, AstraZeneca, Bayer, UCB, Boehringer Ingelheim and Sanofi. Among sponsors and exhibitors, the majority are specialist software and data vendors selling into that function, spanning genomics and sequencing (Illumina, QIAGEN), data platforms and cloud (Snowflake, Neo4j, Nebius), life-sciences informatics (Genedata, DNAnexus, Schrödinger, Ardigen) and AI/data consultancies (EPAM, ThoughtWorks, Cognizant, Globant). A third group, smaller in number but named separately by the organiser, is the roughly one hundred biotech start-ups in the exhibitor zone. Large medical-device manufacturers and hospital-equipment vendors, the kind that dominate a trade fair like MEDICA, are not represented on the published sponsor list.
Not publicly disclosed as a distinct process. What is published is a complimentary press and media pass, offered on the same registration page as the paid tiers, with no separate accreditation form, criteria or deadline described. No dedicated media or press contact was found on the event's own pages; enquiries would have to go through the general sales or marketing contacts named for this event.
None found in independent media. Searches across news sources returned listing pages (trade-fair directories, association calendars, exhibitor-services sites) rather than independent editorial coverage of the 2026 edition. No media partner is recorded for this event in the database, and none was found labelled as such on the organiser's own partner page, which lists national biotech and professional associations instead.
There is nothing to qualify, and that is itself the finding. Organiser-arranged: no media partner found. Independent but promotional: none found. Predictable but not yet coverage: not assessed, no journalist was identified among the sampled speakers. Organiser-claimed but unverified: the attendance, speaker and exhibitor figures (3,000+, 400+, 150+) are all organiser-published and none is described as audited. A journalist or analyst should treat 2026 coverage of this event as effectively unreported outside Terrapinn's own channels until the congress itself takes place.
Three groups. Anyone whose interest is biologics, cell and gene therapy or antibody manufacturing: that programme runs the following week at the same venue, as the separately ticketed Festival of Biologics Basel, not as part of this congress. Buyers looking for a hardware or medical-device sourcing floor: the sponsor list is data, AI and bioinformatics software, not devices or diagnostics equipment, which sits closer to MEDICA in Düsseldorf. And anyone who needs a firm, published price before committing budget: BioTechX Europe currently shows three different numbers for its cheapest ticket across its own landing banner, its live registration page and the database record checked for this fiche, and the early-bird deadline is 18 September 2026, a week away.
It sits in a dense autumn run of Terrapinn and adjacent life-sciences events. BioTechX USA runs in Boston on 29 to 30 September 2026, a week before this edition. BioTechX Europe follows on 6 to 8 October 2026 in Basel. The Festival of Biologics Basel, a separate Terrapinn congress on biologics and cell and gene therapy, runs at the same venue the following week, 13 to 15 October 2026. MEDICA, the large medical-technology trade fair, follows in Düsseldorf on 16 to 19 November 2026 (unverifiable information: date drawn from the fair's own current listing, not cross-checked against a second source). HLTH Europe, a broader digital-health executive and investor event in Amsterdam, ran earlier in the year, 15 to 18 June 2026, and had already taken place by the time this fiche was verified. Against that calendar, BioTechX Europe is the specialist entry for pharma R&D data and AI specifically, narrower than MEDICA or HLTH Europe and distinct in subject from the biologics congress that follows it in the same hall.
Yes. BioTechX USA runs at the Hynes Convention Center in Boston, Massachusetts, on 29 to 30 September 2026, a separate registration and a separate site from BioTechX Europe, confirmed on the organiser's own BioTechX USA pages. No BioTechX edition outside Basel and Boston was found.
Not stated. No language is declared on the event's own pages. All published material, including the programme themes and speaker titles, is in English, and the sponsor and speaker rosters are drawn from across Europe and beyond, which makes English the working language in practice; interpretation into other languages is neither offered nor ruled out on the pages checked.
No. The organiser's own FAQ states plainly that sessions are not recorded, and encourages attendees to connect with speakers directly through the event app for materials instead. No livestream, virtual pass or on-demand library is offered.
Not publicly disclosed. No terms and conditions, cancellation window or transfer clause was found on the event's own pages or FAQ. The FAQ addresses dress code (business casual) and badge collection but not cancellation.
The organiser's own FAQ states that the venue is fully accessible, describing Messe Basel as equipped with facilities for disabled guests, with further detail pointed to the venue's own pages. No specific request process or contact for access needs is published on the event's own site.
Messe Basel sits at Messeplatz in central Basel. By the venue's own published routing: from EuroAirport Basel-Mulhouse-Freiburg, bus line 50 connects to Basel SBB railway station, from where tram lines 1 or 2 reach the Messeplatz stop directly outside the halls, a roughly ten-minute tram ride. From Zurich Airport, a direct rail connection reaches Basel SBB in under an hour. The venue is also a short walk from the Badischer Bahnhof and SNCF stations. This routing describes the venue in general and was not confirmed against a BioTechX-specific travel page, since none was found on the event's own site.
Because the two are sourced differently. The confirmed 2026 speaker page names individuals with titles that check out: a Chief Data & Digital Officer at Novartis, a Global AI Product Owner at Roche, a VP of R&D Data Science & AI at Bayer, all verifiable against the companies they claim. The attendance, speaker and exhibitor counts (3,000+, 400+, 150+) are a different kind of claim: organiser-published aggregates with no audit trail behind them. A buyer weighing whether to fly to Basel should read the named roster, which is checkable, and treat the round numbers as marketing until the room is actually counted.
Because a congress four weeks out should be able to state its own price once. This fiche found three different numbers for the cheapest BioTechX Europe ticket: €2,495 in the database record, €2,695 on the event's own landing banner, and €2,795 as the actual early-bird floor on the live registration page. None of the three is wrong in the sense of being fabricated, they are more likely three snapshots of the same page at different points in its pricing calendar, left uncorrected. But an organiser that cannot keep its own headline price consistent across its own pages is not a strong source for the attendance and speaker figures it publishes with no backing at all. Where this fiche could check a number, it used the live registration page; where it could not, it says so.
Official site: https://www.terrapinn.com/conference/biotechx/index.stm. Conference and agenda: https://www.terrapinn.com/conference/biotechx/Conference.stm and https://www.terrapinn.com/conference/biotechx/agenda.stm. Confirmed speakers: https://www.terrapinn.com/conference/biotechx/speakers.stm. Sponsors and exhibitors: https://www.terrapinn.com/conference/biotechx/sponsors-and-exhibitors.stm. Supporting partners: https://www.terrapinn.com/conference/biotechx/Supporting-Partners.stm. Frequently asked questions: https://www.terrapinn.com/conference/biotechx/frequently-asked-questions.stm. Registration: https://secure.terrapinn.com/V5/step1.aspx?E=11044. Apply to speak or sponsor: https://secure.terrapinn.com/v5/edetails.aspx?e=11044. BioTechX USA (separate event): https://www.terrapinn.com/conference/biotechxusa/.